An Australian law firm is launching a class action against the manufacturer of Nurofen after its 'Specific Pain' range of four products were found to all have the same ingredients.

In December 2015, the Federal Court found in favour of the Australian Competition and Consumer Commission (ACCC) - who earlier in the year brought a suit against parent company Reckitt Benckiser.

The Federal Court ruled Reckitt Benckiser engaged in misleading conduct by claiming its Specific Pain products were formulated to treat a specific type of pain.

The four products - Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension Headache - all, in fact, contained the exact same active ingredient: ibuprofen lysine 342mg.

Doctor Vivienne Miller was disgusted at the marketing ploy, having encountered many patients who were popping multiple tablets for multiple ailments.

"Patients may double dose and they may have back pain and a headache, and they may not realise the medication they are taking is the same dose," Dr Miller said.

"A lot of people in the medical profession had alarm bells."

Lawyer Charles Bannister is planning on bringing about legal pain for the company that were meant to be relieving people's physical pain.

"It's a staple item in the Australian household. We are looking at millions of Australians who have purchased these items since 2011," Mr Bannister said.

"They exploited consumers and they were misleading."

Four of Nurofen's Specific Pain range products were found to have contained the exact same key active ingredient, despite being marketed to treat different ailments (Source: A Current Affair)

Lawyer Charles Bannister is hoping those with chronic ailments who purchased the products will join his class action against Reckitt Benckiser, the manufacturer and marketer of Nurofen (Source: A Current Affair)